Mesdopetam for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease: A Randomized Phase 2b Trial
Movement Disorders Clinical Practice · 2025
DOI: 10.1002/mdc3.70004 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Movement Disorders Clinical Practice, 2025. Verfasst von Angelo Antonini und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, University of Padua, Padova, Italy. Hauptthemen laut MEDLINE: Parkinson Disease, Levodopa, Dyskinesia, Drug-Induced, Antiparkinson Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
The treatment of levodopa‐induced dyskinesia in Parkinson's disease (PD) is a largely unmet need.
Objectives
Mesdopetam is a novel small molecule dopamine D3 receptor antagonist aimed for the treatment of levodopa‐induced dyskinesia. This was a phase 2b study dose finding study to investigate efficacy and safety of 2.5 mg, 5 mg and 7,5 mg b.i.d. in a randomized controlled trial.
Methods
PD patients with ≥2 hours of troublesome dyskinesia were randomized to placebo or mesdopetam twice daily for 12 weeks. The primary efficacy endpoint was change from baseline to week 12 in ON time without troublesome dyskinesia (Good ON‐time) as recorded with home diaries. Secondary efficacy endpoints assessing ON phase dyskinesia were the modified UDysRS (sum of parts 1, 3 and 4) and MDS‐UPDRS part 4.2.
Results
Groups did not differ in change from baseline to end of study in Good ON‐time. Several secondary assessments for ON phase dyskinesia such as the modified UDysRS showed clinically relevant and statistically significant improvements for the 2.5 and 7.5 mg doses. OFF time showed dose dependent decrease with highest efficacy for the 7.5 mg dose. The adverse event profile was similar to placebo.
Conclusions
In this study mesdopetam failed to increase Good ON‐time as compared to placebo. However, a statistically significant and clinically meaningful improvement in the prespecified secondary efficacy endpoint UDysRS warrants further investigation. Results from this dose finding study suggest 7.5 mg b.i.d. to be the preferred dose for further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, University of Padua, Padova, Italy.
- Department of Neurology and Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- University San Raffaele Rome and Institute for Research and Medical Care (IRCCS) San Raffaele, Rome, Italy.
- Integrative Research Laboratories Sweden AB (IRLAB), Göteborg, Sweden.
ORCID-Profile: Padraig O'Suilleabhain, Fabricio Stocchi, Susanna Waters
Zitieren
APA
Antonini, A., O'Suilleabhain, P., Stocchi, F., Landström, J., Waters, S., Sonesson, C., & Tedroff, J. (2025). Mesdopetam for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease: A Randomized Phase 2b Trial. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.70004
Vancouver
Antonini A, O'Suilleabhain P, Stocchi F, Landström J, Waters S, Sonesson C, et al. Mesdopetam for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease: A Randomized Phase 2b Trial. Movement Disorders Clinical Practice. 2025. doi:10.1002/mdc3.70004
BibTeX
@article{Antonini2025,
author = {Antonini, Angelo and O'Suilleabhain, Padraig and Stocchi, Fabricio and Landström, Johanna and Waters, Susanna and Sonesson, Clas and Tedroff, Joakim},
title = {Mesdopetam for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease: A Randomized Phase 2b Trial},
journal = {Movement Disorders Clinical Practice},
year = {2025},
doi = {10.1002/mdc3.70004}
}
EUVIMED